preview fine tune estim base novarti lilli
reiter market outperform rate price target
incyt corpor base discount earn per share revenu
multipl analysi recent novarti nv nc report jakavi sale
separ lilli nc report world-wid olumi sale
estim translat approxim
total royalti consensu rux expect gener
 sale recent approv pemigatinib cholangiocarcinoma
novarti file sr-agvhd world-wide posit phase result report
compani dermatolog franchis cash posit pro forma
continu recommend share
jakavi sale novarti report jakavi sale translat
approxim estim previou estim
royalti consensu repres
strong quarter-over-quart growth novarti state addit demand
across compani portfolio driven forward purchas europ
china due pandem
olumi sale lilli report world-wid olumi sale
 ex-u quarter-over-quart increas
translat estim previou estim
royalti consensu lilli state growth due
increas volum like novarti lilli report stock occur
due pandem underli sale trend remain
strong even account effect
account tafasitamab collabor licens agreement
payment follow guidanc manag payment
global collabor licens agreement tafasitamab see note
expect account includ up-front payment
equiti invest premium morphosi mor mo pt butler
 expens figur remain equiti invest
mor total equiti invest premium expect
reflect balanc sheet mark market end quarter
potenti forward purchas effect due pandem
novarti lilli report increas sale due stock effect
anticip least meet sale expect beat
quarter although full effect pandem revenu beyond
harder predict expect meet previou guidanc given
sever indic compani drug treat
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
figur updat jmp estim consensu
figur guidanc updat jmp estim
updat figur million except per share estim previou jmp estim iclusig product total non- expens non- net incom loss net incom loss non- ep -dilut ep tafa-rel expensesguid figur million except per share estim previou guidancejmp estim updat exclud exclud exclud tafa sg exclud exclud exclud tafa sg figur incom statement quarterli
incyt corpor incom statementfigur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad -- -- -- -- -- -- tafasitamab dlbcl cll pemigatinib cholangio uc -- total product revenu product royalti contract revenue- mileston revenue- total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss unreal gain loss long term investments- interest incom expens non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor figur incom statement annual
incyt corpor incom statementfigur thousand except per share revenu jakafi itacitinib gvhd iclusig eu rux cream ad tafasitamab dlbcl cll pemigatinib cholangio uc total product revenu product royalti contract revenue- mileston revenue- total non- total non- expens good research sell gener chang fair valu acquisition-rel conting consideration- total non- total non- incom loss unreal gain loss long term investments- interest incom expens non- net loss incom incom incom tax expens non- net loss incom common non- net loss incom earn per share basic dilut basic dilut averag share outstand dilut incyt corpor incyt corpor
wilmington delaware-bas incyt corpor drug discoveri develop compani grow pipelin novel small-molecul
drug treat variou inflammatori disord cancer
risk invest thesi valuat includ clinic develop competit regulatori sector
clinic develop risk drug develop riski capital-intens endeavor major drug enter clinic develop
fail reach market
competit risk drug market develop condit program address lack
differenti clinic data drug and/or approv competit drug may advers impact sale potenti product
regulatori risk like drug develop compani reliant upon fda pace evalu new drug agenc
willing approv new drug
sector risk valuat biotechnolog stock subject investor assess prospect underli compani investor
toler risk confid prospect biotechnolog stock group therefor stock price may fall even
compani meet exce investor expect
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign reni benjamin
jmp secur current make market secur incyt corpor compani morphosi ag novarti ag
jmp secur expect receiv intend seek compens invest bank servic incyt corpor morphosi
ag next month
disclaim detail pleas click link
applic disclosur compani mention report pleas refer jmp fact disclosur page report link
market outperform mo jmp secur expect stock price outperform relev market indic next month
market perform mp jmp secur expect stock price perform line relev market indic next month
market under-perform mu jmp secur expect stock price under-perform relev market indic next month
jmp secur research rate invest bank servic may
co
servic
stock price chart rate price chang
note first annot denot initi coverag year whichev shorter target price list target price n/a
accord finra rule chart reflect price rang chang rate price target end
recent calendar quarter action reflect note annot stock price chart jmp secur
jmp secur llc firm compens research analyst like firm employe base firm profit includ
revenu firm institut sale trade invest bank depart well qualiti servic activ
perform intend benefit firm institut client data prepar jmp secur llc inform
purpos base inform avail public sourc believ reliabl guarante
accuraci complet opinion project express herein reflect judgment date subject chang
without notic data neither intend consid offer sell solicit basi contract
purchas secur financi product jmp secur llc affili jmp group llc harvest capit strategi llc
respect partner director offic associ may long short posit may act market maker may
purchas sell posit secur mention herein jmp secur llc affili may perform perform seek
perform invest bank advisori servic may act manag co-manag public offer secur
compani mention herein reader assum jmp secur llc solicit busi compani cover
report member sale trade depart provid oral and/or written market opinion trade strategi client
reflect person opinion stock subject firm research report research analyst discuss trade
strategi client sometim reflect short-term expect price secur subject research report
trade strategi distinct analyst fundament rate stock base upon analyst view compar
stock coverag relev time period copyright right reserv jmp secur llc jmp secur
llc member finra sipc
director research
director equiti
director sale trade
